Investigating the impact of somatostatin analogues on tumor dose during radionuclide therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate how long-acting somatostatin analogues (LA-SSA) affect the absorbed dose in tumor lesions during peptide receptor radionuclide therapy (PRRT) for patients with neuroendocrine tumors. Patients aged over 18 with confirmed neuroendocrine tumors are randomized into two groups: one that discontinues LA-SSA prior to PRRT and another that continues LA-SSA treatment. The study will assess the effectiveness of these approaches in improving treatment outcomes. The trial is conducted in collaboration with the Neuroendocrine Tumor Research Foundation at the Netherlands Cancer Institute.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years;
* Able to provide spoken and written informed consent for the trial;
* Histopathological confirmed neuroendocrine tumor;
* Fulfill the clinical criteria for PRRT;
* At least one soft tissue lesion \> 2 cm;
* Aimed administered activity of 7400 MBq;
* ECOG score (performance status) 0-2.

Exclusion Criteria:

* Not possible to discontinue LA-SSA for 4-6 weeks;
* Use of short-acting SSAs;
* Pregnancy and lactating female patients;
* Inability to comply to the study procedures;
* Factors that might affect the biodistribution (for example, indication for furosemide directly after PRRT infusion, limited fluid intake, any renal catheters, etc.).

Where it's running

• Antoni van Leeuwenhoek
  Amsterdam, Netherlands Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Exploring new biomarkers for diagnosing and treating neuroendocrine tumors

  This study is testing new ways to diagnose and treat neuroendocrine tumors by looking at blood samples to see if they can provide better information about the cancer.

  Recruiting University of Roma La Sapienza · Rome, Italy · NCT04464122

• Comparing two doses of Everolimus for treating neuroendocrine tumors

  This study is testing whether a lower dose of Everolimus can effectively treat patients with advanced neuroendocrine tumors while causing fewer side effects compared to a higher dose.

  Recruiting at 2 sites Phase 2 AC Camargo Cancer Center · São Paulo, São Paulo and 1 other locations · NCT06472388

• Customized Lutetium-177 treatment for neuroendocrine tumors

  This study is testing if a personalized dose of Lutetium-177 can improve treatment results for adults with hard-to-treat neuroendocrine tumors compared to standard treatment.

  Recruiting Phase 2 University of Iowa · Iowa City, Iowa · NCT06395402

• CTX-471 for NCAM-positive metastatic neuroendocrine tumors

  A phase 2 trial is testing CTX-471 in adults with NCAM (CD56) positive metastatic neuroendocrine tumors that have progressed after standard therapy.

  Recruiting at 2 sites Phase 2 Compass Therapeutics · St Louis, Missouri and 1 other locations · NCT07684170

• Combination therapy for Grade 2 liver-dominant neuroendocrine tumors

  This study is testing a new combination treatment of two drugs followed by a special radiation therapy to see if it helps people with Grade 2 liver-dominant neuroendocrine tumors live longer without their cancer getting worse.

  Recruiting Phase 2 Abramson Cancer Center at Penn Medicine · La Jolla, California and 4 other locations · NCT04339036

• Somatostatin analogues after PRRT for nonfunctional neuroendocrine tumors

  This study tests whether continuing somatostatin analogues after PRRT helps patients with nonfunctional neuroendocrine tumors compared with just observation.

  Recruiting Phase 3 Washington University School of Medicine · San Francisco, California and 1 other locations · NCT07842172

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.